RT Journal Article
SR Electronic
T1 The Role of Genomic-Informed Risk Assessments in Predicting Dementia Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.27.24306488
DO 10.1101/2024.04.27.24306488
A1 Andrews, Shea J.
A1 Jonson, Caroline
A1 Fulton-Howard, Brian
A1 Renton, Alan E
A1 Yokoyama, Jennifer S
A1 Yaffe, Kristine
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/04/30/2024.04.27.24306488.abstract
AB Importance By integrating genetic and clinical risk factors into genomic-informed dementia risk reports, healthcare providers can offer patients detailed risk profiles to facilitate understanding of individual risk and support the implementation of personalized strategies for promoting brain health.Objective To develop a genomic-informed risk assessment composed of family history, genetic, and clinical risk factors and, in turn, evaluate how the risk assessment predicted incident dementia.Design This longitudinal study included data from two clinical case-control cohorts with an average of 6.6 visits. Secondary analyses were conducted from July 2023 - March 2024.Setting Data were previously collected across multiple US locations from 1994 to 2023.Participants Older adults aged 55+ with whole-genome sequencing and dementia-free at baseline.Exposures An additive score comprising the modified Cardiovascular Risk Factors, Aging, and Incidence of Dementia Risk Score (mCAIDE), family history of dementia, APOE genotype, and an AD polygenic risk score.Main Outcome(s) and Measure(s) The risk of progression to all-cause dementia was evaluated using Cox-proportional hazard models (hazard ratios with 95% confidence intervals [OR 9%CI]).Results A total of 3,429 older adults were included (aged 75 ± 7 years; 59% female; 75% non-Latino White, 15% Black, 5.2% Latino, 3.6% other, and 0.4% Asian; 27% MCI), with 751 participants progressing to dementia. The most common high-risk indicator was a family history of dementia (56%), followed by APOE*ε4 genotype (36%), high mCAIDE score (34%), and high AD-PRS (11%). Most participants had at least one high-risk indicator, with 39% having one, 32% two, 9.8% three, and 1% four. The presence of 1, 2, 3, or 4 risk indicators was associated with a doubling (HR = 1.72, CI: 1.34-2.22, p = 2.5e-05), tripling (HR = 3.09, CI: 2.41-3.95, p = 4.4e-19), quadrupling (HR = 4.46, CI: 3.34-5.94, p = 2.2e-24), and a twelvefold increase (HR = 12.15, CI: 7.33-20.14, p = 3.2e-22) in dementia risk.Conclusion & Relevance We found that most participants in memory and aging clinics had at least one high-risk indicator for dementia. Furthermore, we observed a dose-response relationship where a greater number of risk indicators was associated with an increased risk of incident dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSJA is supported by the National Alzheimers Coordinating Center New Investigator AwardAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used publically available data from the Alzheimers Disease Neuroimaging Initiative (https://adni.loni.usc.edu/) and National Alzheimers Coordinating Center (https://naccdata.org/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://naccdata.org/ https://adni.loni.usc.edu/ https://www.niagads.org/